RopesTalk

In this episode of Women @ RopesTalk, hosted by IP transactions partner Megan Baca, M&A partner Emily Oldshue speaks with Siobhan Pomeroy, vice president of corporate development at leading biopharmaceutical company Gilead Sciences. With a background in science and an MBA, Siobhan talks about the many business and corporate development roles she’s held across the life sciences industry, including at a medical device firm, smaller biotech companies and larger pharmaceutical companies. She plots her trajectory to her current role as a leader of transaction teams and gives her invaluable perspective on team building. Thinking about her career, she remembers a deal where her personal and professional lives collided, and shares the advice she gives to women colleagues who ask her about work-life balance.

Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2023. This fourth episode will feature a lightning round where we cover additional insights on expected developments not covered earlier in the series. Topics discussed include anticipated guidance on drug compounding, advertising and promotion, the redesign of the Human Foods Program, and more.

Co-hosts Zach Coseglia and Hui Chen explore the power of storytelling with Megan Zwiebel, the “untangler of knots” and director of operations and delivery at R&G Insights Lab, who went from working as a litigation attorney to anti-corruption journalist, and now as the person who makes the trains run on time at the Insights Lab. Along the way, she shares insights about uncovering juicy fact patterns in corruption cases, the need for organizations to take narrative control of their identities, and the human beings who read legal briefs.

In this Ropes & Gray podcast, asset management partners Jason Kolman and Jessica Marlin discuss the latest market trends in rated note structures. They discuss how these feeders into private credit funds respond to regulatory capital preferences of insurance company investors, key differences compared to traditional fund structures, the latest terms in the market, and navigating the ratings agency process. 

Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2023. This third episode will focus on what we except to see in the courts throughout 2023. Topics discussed include litigation challenges against the agencies, enforcement litigation by the government and other matters.

Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2023. This second episode will focus on anticipated policy developments from FDA and CMS in 2023. Topics discussed include rulemaking implications of the Food and Drug Omnibus Reform Act (FDORA), accelerated approval reform, potential digital health device and cybersecurity guidance, the end of the public health emergency, the Inflation Reduction Act, Part D reforms, and CMMI and HRSA action around the 340B program.

In this Ropes & Gray podcast, asset management partners Nicole Krea and Joel Wattenbarger discuss three recent headline items in regulatory compliance for private funds: first, the new marketing rule FAQ, with respect to extracted performance; second, the recently released Regulatory Flex Agenda; and, third, the SEC's 2023 exam priorities. The Private Fund Regulatory Update is a series of podcasts discussing key issues of interest and updates in the regulatory and compliance space, focusing in particular on private fund managers.

Join Ropes & Gray’s life sciences and health care attorneys on a four-part podcast series exploring regulatory, compliance and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2023. This first episode will focus on key developments from 2022 that we expect to continue to be significant in 2023. Topics discussed include the Inflation Reduction Act, the Food and Drug Omnibus Reform Act (FDORA), possible legislative action related to orphan drug exclusivity, and the full resumption of domestic and international FDA inspections. 

In this episode of There Has to Be a Better Way?, co-hosts Zach Coseglia and Hui Chen interview their colleague at R&G Insights Lab, Dr. Caitlin Handron, about cultural psychology, her field of study. She discusses how cultural factors influence human behavior and how integrating insights from the social sciences can help companies tackle organizational challenges—from compliance programs to diversity, equity and inclusion—in more effective ways.

Over the past few decades, the ITC has become increasingly focused on intellectual property—and specifically patent—disputes between domestic companies. According to some legislators and commentators, this shift has led the application of Section 337 astray from its original intent: adjudicating unfair trade practices in the importation of goods from foreign countries. Thus, over the past decade, there have been a number of proposed tweaks to Section 337, or the ITC more generally, to address issues like alleged non-practicing entity abuse of the ITC or alleged unfair trade practices implemented by China, such as forced technology transfer. In this episode of Talkin’ Trade, Ropes & Gray IP litigators Matt Rizzolo, Matt Shapiro, Brendan McLaughlin, and Nancy Attalla discuss some of the recent proposals and how they would change Section 337 practice.